Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
144
resultados
Última actualización
16/04/2026 [07:37:00]
Resultados 125 a 144 de 144
Resumen de: CN120789208A
The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for treating ulcerative colitis as well as a preparation method and application thereof. The invention discloses a traditional Chinese medicine composition for treating ulcerative colitis. The traditional Chinese medicine composition comprises the following components in parts by weight: 20-60 parts of codonopsis pilosula, 10-50 parts of roasted rhizoma atractylodis macrocephalae, 10-50 parts of roasted radix aucklandiae, 10-50 parts of parched white peony root, 10-50 parts of rhizoma cimicifugae, 10-50 parts of bran-fried Chinese yam, 10-50 parts of myristica fragrans, 20-40 parts of vinegar smoked plum, 10-30 parts of fried fructus chebulae, 10-30 parts of baked ginger and 5-45 parts of honey-fried licorice root. According to the traditional Chinese medicine composition provided by the invention, the level of a proinflammatory marker is remarkably reduced, the balance of M1/M2 macrophages in colon tissues is regulated, the damage of oxidative stress to the colon mucosal barrier can be effectively reversed, and the expression of a PI3K/AKT/mTOR signal channel and HIF-1alpha is regulated, so that the curative effects of relieving inflammatory response and accelerating repair are achieved.
Resumen de: WO2025214468A1
Provided are a new antibody and antibody fragment that specifically bind to IL-15, and a composition containing the antibody or antibody fragment. Furthermore, provided are a nucleic acid encoding the antibody or antibody fragment thereof, a host cell containing same, and the related use. In addition, provided are the therapeutic and diagnostic uses of the antibodies and antibody fragments.
Resumen de: US2025319052A1
This present invention relates to the use of eicosapentaenoic acid (EPA) for the treatment of ulcerative colitis (UC), and more particularly, the use of highly purified eicosapentaenoic acid as free fatty acids (EPA-FFA) having a purity of at least 95% for reducing inflammation in a subject suffering from ulcerative colitis and wherein the levels of IL-10 and SOCS3 are increased and the microbiome of the intestinal mucosal tissue is favorably modulated.
Resumen de: US2025321218A1
The present disclosure provides methods of selecting a treatment for an inflammatory bowel disease in a subject. In particular, using an indicator of epithelial absorption and metabolism the present disclosure provides method for determining the likelihood a subject is responsive or non-responsive to an inflammatory bowel disease therapeutic agent. The method includes providing a baseline measurement of a microvillus length in the small intestine of a subject, selecting a treatment for the subject according to a treatment criteria, and administering the treatment to the subject.
Resumen de: EP4632080A2
This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.
Resumen de: CN120775993A
The invention belongs to the field of molecular genetics, and particularly relates to an SNP (Single Nucleotide Polymorphism) molecular marker combination for genetic relationship identification of wuzhu cattle and application of the SNP molecular marker combination. The SNP marker combination is composed of 140 high-polymorphism SNP sites distributed on a plurality of chromosomes of a bovine whole genome, the average distance between the sites is reasonable, and the SNP marker combination has good genome coverage. The selected SNP site has high allele frequency (MAF), expected heterozygosity (He) and polymorphic information content (PIC), and the cumulative exclusion probability is 0.9999. King and Plink software are combined to deduce a genetic relationship coefficient (Kinship) and an IBD shared value (PIHAT) between samples, and a result shows that the marker combination can realize a genetic relationship recognition effect equivalent to that of whole genome SNP data in Wuzhu white cattle (grassland white cattle), and the scientificity and practicability of the marker combination are verified. The SNP molecular marker combination can be widely applied to the processes of germplasm resource management, pedigree correction and cattle breeding, and has good popularization prospects and economic benefits.
Resumen de: KR20250148382A
본 발명은 염증성 장질환(inflammatory bowel disease, IBD) 진단 및 치료를 위한 miRNA 바이오마커를 제공한다. 본 발명의 일 실시예에 따른 바이오마커는 염증성 장질환 진단용 조성물, 진단을 위한 정보 제공 방법, 염증성 장질환 예방 또는 치료용 약학 조성물, 염증성 장질환을 치료하는 방법 및 염증성 장질환 치료제의 스크리닝 방법에 활용될 수 있다.
Resumen de: CN120758646A
The invention discloses a tetraploid crassostrea gigas parent-child relationship identification method based on SNP sites, and belongs to the technical field of tetraploid crassostrea gigas molecular assisted breeding. The method for identifying the parent-child relationship of tetraploid crassostrea gigas comprises the following steps: (1) sequencing adductor muscles of tetraploid crassostrea gigas to be detected; (2) comparing the reference genome of the crassostrea gigas to obtain the genotype of the specified SNP site of the tetraploid crassostrea gigas; (3) calculating IBS and LOD of the to-be-detected parents and the to-be-detected offspring according to an SNP typing result; and (4) identifying the parent-child relationship between the to-be-detected parent and the filial generation by combining IBS and LOD. The SNP loci have the advantages that 1000 SNP loci for identifying the parent-child relationship of the tetraploid crassostrea gigas are disclosed for the first time, data support is provided for identifying the parent-child relationship of the tetraploid crassostrea gigas, a foundation is laid for developing a liquid phase chip for identifying the parent-child relationship of the tetraploid crassostrea gigas, and the SNP loci have good application prospects.
Resumen de: US2025313880A1
Methods and materials are disclosed for testing biomarkers in a subject suffering from inflammatory bowel disease (IBD) are described herein. Such detection can be useful for diagnosing and treating ulcerative colitis (UC) and Crohn's disease (CD), two forms of IBD that are otherwise difficult to distinguish. The method includes measuring the level of one or more of several biomarkers, including HD5 or MMP-7, which are expressed differentially in patents with UC and CD. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohn's disease.
Resumen de: US2025313613A1
The present disclosure relates to: a method, a composition, and a method for producing the same for treating IBD using gastrointestinal contents or excretions modified with an IgA antibody; a method for obtaining an IgA antibody that restores the bacterial flora in the gastrointestinal tract of an IBD patient; a method, a composition, and a method for producing the same for modifying gastrointestinal contents or excretions of an IBD patient using an IgA antibody; and a method, a composition, and a method for producing the same for testing with the diagnostic pharmaceutical drug containing an IgA antibody in a patient treated with the IBD therapeutic agent containing gastrointestinal contents or excretions.
Resumen de: US2025305068A1
The present invention relates to a new biomarker of inflammatory bowel disease and its uses. The new biomarker is a ratio of Dialister spp. to Phascolarctobacterium spp. This biomarker can be used for diagnosis purpose of diseases or disorders associated with an intestinal dysbiosis, for stratifying patient population in a clinical trial, for selecting a subject that will benefit from a treatment, or for monitoring treatment response. The present invention further provides new therapeutic strategies.
Resumen de: US2025304705A1
The present disclosure relates to an orthogonal system comprising a first bi-specific polypeptide that comprises D-streptavidin or a variant thereof covalently linked to an antibody or antibody fragment and a second bi-specific polypeptide that comprises L-biotin covalently linked to a therapeutic or diagnostic agent. The disclosed systems can be useful in, for example, treating a disease or a condition (e.g., cancer, non-Hodgkin lymphoma, multiple sclerosis, Crohn's disease, rheumatoid arthritis, asthma, macular degeneration, psoriasis, Hodgkin lymphoma, paroxysmal nocturnal hemoglobinuria, X-linked hypophosphatemia). Also described are peptides and polypeptides useful in preparing the disclosed bi-specific polypeptides and methods of making same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Resumen de: US2025302891A1
Provided herein are methods for detecting inflammatory bowel disease (IBD) or risk of IBD in a canine based on the canine's gut microbiome. Also provided are methods for treating or preventing IBD in canines. Finally provided are probiotic compositions that are used in the methods of the present disclosure.
Resumen de: WO2025206567A1
The present invention provides a miRNA biomarker for diagnosing and treating inflammatory bowel disease (IBD). A biomarker according to one embodiment of the present invention can be utilized in a composition for diagnosing inflammatory bowel disease, a method for providing information for diagnosis, a pharmaceutical composition for preventing or treating inflammatory bowel disease, and a method for treating inflammatory bowel disease.
Resumen de: AU2024236253A1
The present invention relates to an in vitro method for evaluating the state of intestinal permeability of a subject and, consequently, for the diagnosis of diseases or dysfunctions associated with intestinal hyper-permeability. More specifically, the procedure allows measuring using a common food component the amount of dietary antigen that can traverse a dysfunctional intestine. The procedure allows for the development of analytical products and processes within the framework of the medical devices industry.
Resumen de: WO2025202626A1
The present techniques relate to a breath analysis device and a system for using such a breath analysis device. We also describe a method for using the breath analysis device. The breath analysis device comprises a filtering mechanism (which may also be termed a filter stack) for removing interferent chemicals to increase the accuracy of detection, identification and quantification of specific chemicals. Exhaled human breath comprises a multiplicity of vapour phase chemicals and the function of the filtering mechanism is removal, retardation and separation of chemicals other than the specific chemicals to be determined by the sensing element(s). Removal, retardation and separation of the chemicals other than those of interest reduces error by reducing cross sensitivities when using broadly selective sensors such as metal oxide semiconductors. One example use of the breath analysis device may be to enable users who suffer from digestive health problems, particularly irritable bowel syndrome (IBS) or small intestinal bacterial overgrowth (SIBO), to monitor symptoms based on detection of specific chemicals such as hydrogen and/or methane in their breath over time.
Resumen de: JP2025143348A
To provide anti-VP1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.SOLUTION: Antibodies that specifically bind to VP1 of BK virus serotypes I to IV are provided. A method for treating or reducing likelihood of BK virus or JC virus associated disorders is provided. The method comprises administering via injection or infusion to a patient in need an effective amount of the antibody or a pharmaceutical composition, wherein the disorders are nephropathy, BKVAN, hemorrhagic cystitis (HC), progressive multifocal leukoencephalopathy (PML), granule cell neuronopathy (GCN), interstitial kidney disease, ureteral stenosis, vasculitis, colitis, retinitis, meningitis, and immune reconstitution inflammatory syndrome (IRIS).SELECTED DRAWING: None
Resumen de: CN120713972A
The invention discloses a traditional Chinese medicine compound for treating bowel stagnation and a preparation method, and relates to the technical field of traditional Chinese medicine preparation, the compound is prepared from the following raw materials in parts by mass: 12 parts of fried hawthorn, 12 parts of medicated leaven, 9 parts of ginger processed pinellia, 9 parts of poria cocos, 9 parts of pericarpium citri reticulatae, 9 parts of fructus forsythiae, 9 parts of radish seed, 9 parts of immature bitter orange, 9 parts of rhizoma cyperi, 6 parts of mangnolia officinalis, 9 parts of scutellaria baicalensis, 6 parts of coptis chinensis, 25 parts of raw atractylodes macrocephala koidz and 12 parts of rhizoma atractylodis. The medicated leaven in the traditional Chinese medicine compound is fried, so that the carried stale gas can be removed, the bitter taste generated in the subsequent decocting process can be reduced, thin-layer identification is performed on the fried hawthorn and the rhizoma atractylodis, the ratio can be calculated according to the distance from an original point to the center of a main spot and the distance from the original point to the front edge of a developing solvent, and the specific value can be calculated. And the property of the compound is judged, so that the decocted liquid medicine can be improved, and the gastrin level of a patient taking the liquid medicine can be effectively increased.
Nº publicación: CN120719010A 30/09/2025
Solicitante:
JINGMEN CENTRAL HOSPITAL
MAINTAIN BIOMEDICINE WUHAN CO LTD
\u8346\u95E8\u5E02\u4E2D\u5FC3\u533B\u9662,
\u7F8E\u76CA\u6DFB\u751F\u7269\u533B\u836F\uFF08\u6B66\u6C49\uFF09\u6709\u9650\u516C\u53F8
Resumen de: CN120719010A
The invention discloses an intestinal microbial marker related to irritable bowel syndrome, a product and application of the intestinal microbial marker, and belongs to the field of biological medicine. The invention relates to an enteric microbial marker, which is characterized in that the enteric microbial marker comprises one or more of Bacteroides multiforme, Clostridium concealum, Bacteroides ovale and Streptococcus sativus, and the enteric microbial marker comprises one or more of the following components: Bacteroides multiforme, Clostridium concealum, Bacteroides ovale and Streptococcus sativus, and the enteric microbial marker comprises one or more of Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum and Lactobacillus plantarum. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the intestinal microbial marker. The invention provides a product for diagnosing irritable bowel syndrome and a computer program product related to the irritable bowel syndrome. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of the irritable bowel syndrome, and provides a new tool for clinical diagnosis.
BOPI
Sede Electrónica
